Teva Pharmaceutical Industries Ltd (NYSE:TEVA)‘s stock had its “buy” rating reaffirmed by analysts at Leerink Swann in a note issued to investors on Friday.

Several other research firms also recently weighed in on TEVA. Mizuho reissued a “buy” rating and set a $70.00 target price (down previously from $75.00) on shares of Teva Pharmaceutical Industries in a research report on Friday, August 5th. Goldman Sachs Group Inc. downgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $70.00 to $60.00 in a research report on Friday, July 15th. Guggenheim reissued a “buy” rating and set a $80.00 target price on shares of Teva Pharmaceutical Industries in a research report on Monday, August 15th. Oppenheimer Holdings Inc. dropped their target price on shares of Teva Pharmaceutical Industries from $77.00 to $72.00 and set an “outperform” rating on the stock in a research report on Thursday, July 14th. Finally, Jefferies Group dropped their target price on shares of Teva Pharmaceutical Industries from $72.00 to $69.00 and set a “buy” rating on the stock in a research report on Thursday, July 14th. Seven equities research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $67.54.

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Shares of Teva Pharmaceutical Industries (NYSE:TEVA) traded up 0.12% during mid-day trading on Friday, hitting $51.29. 1,506,627 shares of the stock were exchanged. The stock’s 50-day moving average price is $52.11 and its 200-day moving average price is $53.25. The company has a market cap of $46.88 billion, a P/E ratio of 34.26 and a beta of 0.82. Teva Pharmaceutical Industries has a 52-week low of $48.01 and a 52-week high of $66.55.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Thursday, August 4th. The company reported $1.25 earnings per share for the quarter, topping the consensus estimate of $1.20 by $0.05. The company had revenue of $5 billion for the quarter, compared to analysts’ expectations of $4.86 billion. The firm’s revenue for the quarter was up 1.4% on a year-over-year basis. During the same period in the prior year, the firm posted $1.43 EPS. Equities research analysts anticipate that Teva Pharmaceutical Industries will post $5.26 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Thursday, September 8th. Stockholders of record on Monday, August 22nd were given a dividend of $0.34 per share. The ex-dividend date of this dividend was Thursday, August 18th. This represents a $1.36 annualized dividend and a dividend yield of 2.65%.

A number of hedge funds have recently modified their holdings of the stock. Psagot Investment House Ltd. boosted its stake in shares of Teva Pharmaceutical Industries by 81.9% in the second quarter. Psagot Investment House Ltd. now owns 1,070,005 shares of the company’s stock valued at $53,746,000 after buying an additional 481,820 shares during the period. RNC Capital Management LLC boosted its stake in shares of Teva Pharmaceutical Industries by 384.5% in the second quarter. RNC Capital Management LLC now owns 392,970 shares of the company’s stock valued at $19,739,000 after buying an additional 311,856 shares during the period. PGGM Investments boosted its stake in shares of Teva Pharmaceutical Industries by 64.7% in the second quarter. PGGM Investments now owns 1,344,928 shares of the company’s stock valued at $67,556,000 after buying an additional 528,470 shares during the period. Panagora Asset Management Inc. boosted its stake in shares of Teva Pharmaceutical Industries by 216.5% in the first quarter. Panagora Asset Management Inc. now owns 702,480 shares of the company’s stock valued at $37,590,000 after buying an additional 480,509 shares during the period. Finally, Trust Department MB Financial Bank N A boosted its stake in shares of Teva Pharmaceutical Industries by 2.9% in the second quarter. Trust Department MB Financial Bank N A now owns 10,287 shares of the company’s stock valued at $608,000 after buying an additional 287 shares during the period.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. It has a global portfolio of approximately 1,000 molecules.

5 Day Chart for NYSE:TEVA

Receive News & Ratings for Teva Pharmaceutical Industries Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Ltd and related companies with MarketBeat.com's FREE daily email newsletter.